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Intravenous estrogen is not proven
effective for abnormal uterine bleeding:
guidelines are based on flawed evidence
STEPHEN SIMMER, B.A., Wayne State University School of Medicine, Detroit, MI, ssimmer@med.wayne.edu

ABSTRACT
A clinical appraisal and clinical application of: DeVore GR, Owens O, Kase N. Use of intravenous Premarin
Premar in the
treatment of dysfunctional uterine bleeding--aa double
double-blind randomized control study. Obstet Gynecol. 1982 Mar;59(3):285-91.
Mar;59(3):285
This appraisal identifies significant statistical irregularities in the study. A reworking of the study's statistics leads
lea to a conclusion
different from that put forth by the authors of this paper: intravenous estrogen therapy is not, in fact, significantly more effective
compared to placebo therapy for the cessation of acute abnormal uterine bleeding.
bleeding,, intravenous estrogen, conjugated estrogen
Keywords: intravenous Premarin, acute abnormal uterine bleeding

Clinical Context
A 48-year-old
old female patient presented to the emergency department for acute abnormal uterine bleeding (AUB).
She had been bleeding profusely from her vagina for six days. The blood had soaked through her pants, and she
was experiencing lightheadedness, dizziness, and fatigue. Labs revealed a hemoglobin of 5.9 mg/dL. Attempts to
stop the bleeding with megace (40 mg QID) were unsuccessful; the next day, IV estrogen (25 mg in 0.9% NaCl) was
given, and the bleeding stopped.
The use of IV estrogen to control this patient's bleeding was surprising to me. Prior to this case, I had thought
progesterone to be the preferred treatment; it was my understanding tha
thatt progesterone would stabilize the
endometrium by halting proliferation and promoting differentiation, allowing for withdrawal bleeding upon its
2
removal.

Clinical Question
Is intravenous Premarin® (Conjugated Estrogen) effective in the cessation of acute abnormal uterine bleeding?

Research Article
DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding—a
bleeding
double-blind
randomized control study. Obstet Gynecol. 1982 Mar;59(3):285
Mar;59(3):285-91.
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Literature Review
Readily available secondary sources,, including an April 2013 Committee Opinion from the American College of Obstetricians and
(3,4)
Gynecologists , communicate that IV estrogen use is a mainstay medical treatment for acute AUB and reference the study by
DeVore, et al. as sole evidence. Munro, et al. show
showed evidence for high dose medroxyprogesterone acetate,
acetate and Aksu, et al.
(5,6)
compared the use of medroxyprogesterone acetate and combination oral contraceptive pills. This latter study showed
6
effectiveness for both modalities, but not a clinically significant difference between the two. It is surprising that the DeVore, et al.
article would be the only study to evaluate IV estrogen therapy for acute AUB; according to Google Scholar,
Scholar DeVore, et al. is
currently cited in 131 articles. This critical appraisal, therefore, looks at the quality of evidence supporting the use of this treatment
modality and its effectiveness in this case scenario.

Critical Appraisal
This is a randomized, placebo-controlled,
controlled, double
double-blind study. It incorporates an open-label follow-up,
up, demonstrating what should be
Level 1b evidence according to the Oxford Centre for Evidence Based Medicine. The study was ‘partially open’ at the time it was
w
conducted, meaning that if bleeding continued after two cycles of injections, IV estrogen was administered on an open-label
open
basis
regardless of which arm of the study the patient was assigned. This protocol was enacted due to the Human Investigation
Committee’s belief—based
based on common practice at the time
time—that
hat IV estrogen was beneficial and should not be withheld from those
patients in the control group.
The strengths of this study lie in its research methods: randomized, placebo
placebo-controlled, and double-blind.
blind. Considering the number of
subjects used in this study, the investigators performed both a Chi
Chi-square
square test and a Fisher’s exact test for statistical analysis.
Although the authors claim to use an intention-to
to-treat
treat analysis, the number of cases in each group is reported in an inconsistent
manner throughout
ut the paper, and statistical significance is only the result of the authors' failure to assess the data in accordance
with the intent-to-treat
treat standard. At the onset of the study, 16 patients were assigned to the placebo group; however, following the
firstt injections, two of these patients withdrew from the study entirely with no follow
follow-up
up assessment. The study calculates statistical
significance by categorizing the two placebo patients as treatment failures. This is not in line with intent-to-treat protocols, which
state that once a subject is randomized into a treatment group, they cannot be removed when analyzed even if they withdraw from
fr
7
the study or are lost to follow-up.
The study also states that bleeding had stopped after two treatments in 72% of the IV estrogen group and 38% of the placebo group
(p-value
value = 0.021). In order to obtain the 38% placebo response, the authors included the two dropout patients as treatment failures.
failu
However, assuming the two placebo group patients who withdrew had cessat
cessation
ion of bleeding, eight out of the 16 patients in the
placebo arm would have responded. If this were the case, 50% of subjects receiving placebo would have stopped bleeding versus
72% in the treatment group. Using these new values, a Chi
Chi-Square analysis shows
ws that there is no statistical significance between the
IV estrogen group and the placebo group (p-value
value = 0.183) in stopping AUB. This does not prove that IV estrogen is ineffective; in
this study, the authors simply fail to demonstrate that IV estrogen stops AUB more effectively than placebo.
An appropriate critical analysis of this study should include a number needed to treat to determine the realistic value of this
th
medication to a patient. However, in this case a number needed to treat cannot be calculated,, because there is no absolute risk
difference demonstrated between treatment and placebo groups.
Note: This study was funded by a grant by Ayerst Laboratories, the same laboratory that manufactures Premarin®.

Clinical Application
The authors of thiss article skewed their results by assuming that two placebo patients who withdrew and were lost
to follow-up
up would maintain their uterine bleeding. Three lessons can be learned from this critical appraisal:
appraisal first,
that even published authors misrepresent ttheir
heir own data; second, that current guidelines are based on poor
quality evidence; and third, that following guidelines alone is not the same as evidence
evidence-based
based practice. Estrogen
therapy is not without risks, most notably the increased chance of thrombotic events. For example, in one case
8
report, a patient died due to a saddle embolus after six doses of 25 mg of IV estrogen.
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The patient I encountered in the emergency department had symptomatic AUB that was refractory to
progesterone therapy. One potential explanation for the clinical course of this patient is that she received
progesterone followed by estrogen, which the attending physician may have thought to be the clinical equivalent
of combination oral contraceptives. Currently, combination oral contrac
contraceptives
eptives constitute the standard of care.
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